News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-530

Hey Ice,

There are many milestones as WP put it that can propel the SP upwards, one would be the imminent sale of the infusion division, surely it's just days from now the news will break into the market about it's divestment.

That will in my opinion provide funds for 12 month, get's us very close to the break even mark and give the company some breathing space while negotiating with the big boys to fund TAVR.

Also at this stage the refunds this year from the R&D will be greater than the profits that the infusion business provides, so selling the division makes lots of sense.

A good 4C (we said that many times) could also help the SP, although the biggest quarter seems to be the 3rd, so expect July 4C to be a company changer, although 12 month late.

if AV1 (Ratty's) can get to 19 cents, then AHZ should be multiples that what it is now.

I have been in and seen how small caps can turn around very quickly. hang in there.

DYOR